Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Enterprise Value: 2009-2025

Historic Enterprise Value for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $527.3 million.

  • Myriad Genetics' Enterprise Value fell 77.92% to $527.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.7 million, marking a year-over-year decrease of 87.35%. This contributed to the annual value of $1.1 billion for FY2024, which is 20.01% down from last year.
  • Myriad Genetics' Enterprise Value amounted to $527.3 million in Q3 2025, which was up 27.04% from $415.1 million recorded in Q2 2025.
  • Myriad Genetics' Enterprise Value's 5-year high stood at $2.4 billion during Q3 2024, with a 5-year trough of $415.1 million in Q2 2025.
  • Its 3-year average for Enterprise Value is $1.4 billion, with a median of $1.4 billion in 2023.
  • Per our database at Business Quant, Myriad Genetics' Enterprise Value spiked by 249.20% in 2021 and then tumbled by 80.39% in 2025.
  • Myriad Genetics' Enterprise Value (Quarterly) stood at $1.9 billion in 2021, then plummeted by 43.12% to $1.1 billion in 2022, then spiked by 35.01% to $1.4 billion in 2023, then declined by 20.01% to $1.1 billion in 2024, then tumbled by 77.92% to $527.3 million in 2025.
  • Its last three reported values are $527.3 million in Q3 2025, $415.1 million for Q2 2025, and $718.1 million during Q1 2025.